Italprid

Tiapride, the active ingredient in Italprid, is a benzamide antipsychotic presented as an oral dosage form for oral use. It is employed to manage agitation associated with schizophrenia, as well as motor disturbances in Huntington’s disease and chorea. It is indicated for patients who require symptomatic control of psychomotor agitation and for those with neurodegenerative movement disorders.

GNH USA supplies Italprid as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide through regulated distribution channels.

Tiapride is used in the management of disorders involving dopaminergic hyperactivity, particularly in psychiatric and movement‑disorder settings. - Schizophrenia (agitation): reduces psychomotor agitation and improves behavioral stability in patients experiencing acute agitation. - Huntington's disease: alleviates choreiform movements and associated motor symptoms. - Chorea (non‑Huntington): diminishes involuntary movements and improves motor control.

Adverse reactions may occur with Tiapride therapy and should be monitored.

Common Side Effects: - Drowsiness: feeling unusually sleepy or fatigued. - Nausea: mild to moderate stomach upset. - Dry mouth: reduced salivation leading to discomfort. - Dizziness: sensation of light‑headedness or unsteadiness. - Constipation: infrequent bowel movements. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Extrapyramidal symptoms: muscle rigidity, tremor, or abnormal gait. - Neuroleptic malignant syndrome: rare but life‑threatening hyperthermia and muscle breakdown. - Severe hypotension: marked drop in blood pressure causing faintness. - Cardiac arrhythmia: irregular heart rhythm, especially in susceptible individuals. - Suicidal ideation: emergence of thoughts of self‑harm. - Severe depression: marked mood worsening requiring urgent care.

Before initiating Tiapride therapy, clinicians should consider several safety aspects. - Monitor for extrapyramidal symptoms: assess motor function regularly. - Assess cardiovascular status: watch for hypotension or arrhythmias. - Use caution in hepatic impairment: dose adjustment may be required. - Avoid abrupt discontinuation: taper gradually to reduce withdrawal effects. - Pregnancy and lactation: safety not established, use only if benefits outweigh risks. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Tiapride may interact with other medicines; awareness of potential interactions helps maintain safety.

Major Interactions (Avoid): - Concomitant dopamine antagonists: increase risk of extrapyramidal symptoms. - MAO inhibitors: may potentiate hypotensive effects. - QT‑prolonging agents: raise risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors: can raise Tiapride plasma concentrations. - Alcohol: may enhance sedation and dizziness. - Antihypertensive drugs: additive blood‑pressure‑lowering effect.